Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Environmental Management|October 10, 2013
The role of ownership in environmental performance: evidence from coalbed methane developmentTimothy FitzgeraldThe Journal of Dermatological Treatment|June 2, 2020
Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasisAmanda Teeple, Timothy FitzgeraldSleep Disorders|January 20, 2016
Residual Effects of Sleep Medications Are Commonly Reported and Associated with Impaired Patient-Reported Outcomes among Insomnia Patients in the United StatesTimothy Fitzgerald, Jeffrey VietriClimatic Change|August 25, 2020
A sectoral approach allows an artful merger of climate and trade policyGeorge David Banks, Timothy FitzgeraldCase Reports in Radiology|January 19, 2026
Lymphadenopathy in Concurrent Head and Neck MalignanciesTimothy Fitzgerald, Ryan K RigsbyJournal of Drugs in Dermatology : JDD|October 12, 2021
Characteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims DatabaseTimothy Fitzgerald, Amanda Teeple, Terra Slaton, et al.The Journal of Experimental Biology|December 18, 2008
Influence of flexibility on the aerodynamic performance of a hovering wingMarcos Vanella, Timothy Fitzgerald, Sergio Preidikman, et al.Environmental Health Perspectives|May 13, 2011
A review of seafood safety after the deepwater horizon blowoutJulia M Gohlke, Dzigbodi Doke, Meghan Tipre, et al.The Journal of Dermatological Treatment|July 15, 2021
Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured populationChang Xu, Amanda Teeple, Bingcao Wu, et al.Dermatology (Basel, Switzerland)|October 28, 2021
Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured PopulationChang Xu, Amanda Teeple, Bingcao Wu, et al.Pageof 4